Titan Pharmaceuticals IncNASDAQ:TTNP
- LAST PRICE3.9300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.5100/ 5
- Ask / Lots5.0000/ 10
- Open / Previous Close--- / 3.9300
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TTNP |
|---|---|---|
| 11:16 ET | 300 | 3.71 |
| 11:18 ET | 4631 | 3.55 |
| 11:48 ET | 2800 | 3.7 |
| 11:50 ET | 1518 | 3.94 |
| 11:52 ET | 1407 | 3.54 |
| 12:50 ET | 100 | 3.65 |
| 01:04 ET | 1600 | 3.9425 |
| 01:06 ET | 18790 | 4.3 |
| 01:08 ET | 5494 | 3.79 |
| 01:13 ET | 1813 | 3.7901 |
| 01:38 ET | 700 | 4.1772 |
| 01:40 ET | 1956 | 3.832 |
| 02:07 ET | 1100 | 3.92 |
| 02:09 ET | 5100 | 3.8646 |
| 02:12 ET | 3500 | 4.05 |
| 02:16 ET | 3691 | 3.8001 |
| 02:18 ET | 237 | 3.772 |
| 02:20 ET | 121 | 3.79 |
| 02:21 ET | 1032 | 3.94 |
| 02:23 ET | 2895 | 3.8 |
| 02:25 ET | 938 | 3.86 |
| 02:36 ET | 1200 | 3.79 |
| 02:39 ET | 872 | 3.78 |
| 02:41 ET | 1339 | 3.78 |
| 02:48 ET | 315 | 3.75 |
| 02:52 ET | 2211 | 3.75 |
| 02:56 ET | 758 | 3.7508 |
| 03:03 ET | 100 | 3.93 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Titan Pharmaceuticals Inc | 3.6M | -0.6x | --- |
Eastgate Biotech Corp | 3.2M | -0.9x | --- |
Aptose Biosciences Inc | 4.4M | -0.1x | --- |
Processa Pharmaceuticals Inc | 2.9M | -0.2x | --- |
Psyence Biomedical Ltd | 3.0M | -1.1x | --- |
60 Degrees Pharmaceuticals Inc | 1.6M | -0.1x | --- |
Company Information
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
Contact Information
- Headquarters
- SUITE 505, 400 OYSTER POINT BLVDSAN FRANCISCO, CA, United States 94080
- Phone
- 415-244-4990
- Fax
- 650-244-4956
Executives
- Principal Executive Officer, Principal Financial Officer, Director
- Brynner Chiam
- Independent Director
- Avraham Ben-Tzvi
- Independent Director
- Firdauz Edmin Bin Mokhtar
- Independent Director
- Francisco Garcia
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.6M |
|---|---|
Revenue (TTM) | $4.0K |
Shares Outstanding | 914.2K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.14 |
EPS | $-6.59 |
Book Value | $8.50 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 898.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -178,225.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
